share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  10/11 08:03

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a formal notice from The Nasdaq Stock Market, LLC on October 9, 2024. The company's common stock had previously failed to maintain the required $1.00 minimum closing bid price over a 30-day period, but has since achieved compliance by maintaining a closing bid price of $1.00 or more for 20 consecutive trading days starting September 11, 2024. Following this achievement, Allarity issued a press release on October 10, 2024, to announce its regained compliance. The company's CEO, Thomas Jensen, expressed satisfaction with the resolution of the compliance issue and emphasized the company's continued focus on advancing its stenoparib program, particularly the Phase 2 trial for advanced ovarian cancer. Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, with potential therapeutic benefits in cancer treatment due to its unique action on the Wnt signaling pathway. Allarity holds exclusive global rights for the development and commercialization of stenoparib.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a formal notice from The Nasdaq Stock Market, LLC on October 9, 2024. The company's common stock had previously failed to maintain the required $1.00 minimum closing bid price over a 30-day period, but has since achieved compliance by maintaining a closing bid price of $1.00 or more for 20 consecutive trading days starting September 11, 2024. Following this achievement, Allarity issued a press release on October 10, 2024, to announce its regained compliance. The company's CEO, Thomas Jensen, expressed satisfaction with the resolution of the compliance issue and emphasized the company's continued focus on advancing its stenoparib program, particularly the Phase 2 trial for advanced ovarian cancer. Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, with potential therapeutic benefits in cancer treatment due to its unique action on the Wnt signaling pathway. Allarity holds exclusive global rights for the development and commercialization of stenoparib.
Allarity Therapeutics, Inc.，一家臨床階段的生物製藥公司，已成功恢復符合納斯達克的最低買盤價格要求，這一點得到了納斯達克股票市場的正式通知，日期爲2024年10月9日。該公司的普通股此前未能在30天內維持所需的1.00美元最低收盤買盤價格，但自2024年9月11日開始，通過維持1.00美元或更高的收盤買盤價20個連續交易日而實現了符合要求。在取得這一成就後，Allarity於2024年10月10日發表新聞公告，宣佈恢復符合要求。該公司CEO Thomas Jensen對解決符合問題表示滿意，並強調了公司繼續專注於推進其愛文思控股卓倍利巴項目，尤其是用於治療愛文思控股在晚期卵巢癌的2期臨床試驗。卓倍利巴是PARP1/2和Tankyrase 1和2的雙靶抑制劑，由於其對Wnt信號通路的獨特作用，在癌症治療中具有潛在的治療益處。Allarity擁有卓倍利巴的全球獨家開發和商業化權利。
Allarity Therapeutics, Inc.，一家臨床階段的生物製藥公司，已成功恢復符合納斯達克的最低買盤價格要求，這一點得到了納斯達克股票市場的正式通知，日期爲2024年10月9日。該公司的普通股此前未能在30天內維持所需的1.00美元最低收盤買盤價格，但自2024年9月11日開始，通過維持1.00美元或更高的收盤買盤價20個連續交易日而實現了符合要求。在取得這一成就後，Allarity於2024年10月10日發表新聞公告，宣佈恢復符合要求。該公司CEO Thomas Jensen對解決符合問題表示滿意，並強調了公司繼續專注於推進其愛文思控股卓倍利巴項目，尤其是用於治療愛文思控股在晚期卵巢癌的2期臨床試驗。卓倍利巴是PARP1/2和Tankyrase 1和2的雙靶抑制劑，由於其對Wnt信號通路的獨特作用，在癌症治療中具有潛在的治療益處。Allarity擁有卓倍利巴的全球獨家開發和商業化權利。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間